New therapies to Treat Various Rarer Disease will Drive the Enzyme Replacement Therapy Market

Global enzyme replacement therapy market is anticipated to grow at a significant CAGR during the forecast period. The deficiency of certain enzymes results in the progressive accumulation of the deficient enzyme's substrate. Enzyme replacement therapy is one such treatment that is used in the rarer disease to correct the deficient enzyme level. This will drive the enzyme replacement market during the forecast period. Rarer diseases prevalence across the globe is common. According to the World Economic Forum in 2018, it is estimated that 350 million individuals are living with a rare disease. Hence, the huge patient number is anticipated to expand the enzyme replacement therapy market size.

Browse the full report description of "Global Enzyme Replacement Therapy Market Size, Share & Trends Analysis Report By Enzyme Types (Agalsidase Beta, Agalsidase Alfa, Galsulfase, and Others), By Indication (Fabry Disease, Gaucher Disease, Pompe Disease, and Others), Forecast 2019-2025" at https://www.omrglobal.com/industry-reports/enzyme-replacement-therapy-market

Enzyme deficiencies can cause conditions of a rare disease such as Gaucher, Fabry's, and Hunter syndrome. Therefore, the raising cases of such rare disease will also fuel the enzyme replacement therapy industry. Enzyme replacement therapy uses only the human cells to cure the rare disease which minimizes the possibility of reaction and infection. This in turn will drive the adoption of enzyme therapy hence impacting the enzyme replacement therapy market growth.

Additionally, most of the rare diseases are special and don’t have any ethical treatment solutions to it till now. Enzyme replacement therapy is the first enzyme targeted therapy to cure several of these rare diseases. Therefore, the adoption of the therapy is anticipated to increase significantly and drive the enzyme replacement therapy market during the forecast period.

Moreover, many companies are also investing in updating their enzyme replacement therapy product offerings by the addition of new drugs and therapies which will drive the enzyme replacement therapy market considerably.

• In January 2020, Entrada Therapeutics, Inc. announced its engagement in the development of ENTR-501, which is a novel thymidine phosphorylase enzyme replacement therapy. It is indicated for the treatment of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) that affects the digestive and nervous systems of the patient.
• In February 2020, Synspira Therapeutics announced an agreement with the Cystic Fibrosis Foundation to support the development of SNSP003. It is an orally delivered non-porcine enzyme replacement therapy by the Synspira that is designed to treat Malabsorption Syndromes. The development of SNSP003 could represent the first significant enzyme replacement therapy advancement. The SNSP003 enzyme replacement therapy possesses the potential to be the broad-spectrum non-porcine product that addresses malabsorption of fat, protein, and carbohydrates.

Global Enzyme Replacement Therapy Market – Segmentation

By Enzyme Types

• Agalsidase Beta 
• Agalsidase Alfa 
• Galsulfase 
• Others

By Indication

• Fabry Disease 
• Gaucher Disease 
• Pompeo Disease 
• Others

Global Enzyme Replacement Therapy Market- Segment by Region 

North America           

• US
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific    

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East Africa